Asthma disease management - Evidence-based medicine must be dynamic

Journal of Managed Care Pharmacy

Volumn 12, Issue 1, 2006, Pages 80-82

  Curtiss, Frederic R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLUCOCORTICOID; MONTELUKAST; PLACEBO; PREDNISONE; STEROID; THEOPHYLLINE; ZAFIRLUKAST;

ALLERGIC RHINITIS; ASTHMA; CLINICAL TRIAL; EDITORIAL; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MONOTHERAPY; TREATMENT OUTCOME; DISEASE MANAGEMENT; NOTE; UNITED STATES;

ASTHMA; DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; HUMANS; UNITED STATES;

EID: 33646593515     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2006.12.1.80     Document Type: Editorial

References (51)

1. Payakachat N, Summers KH, Barbuto JP. A comparison of clinical practice guidelines in the initial pharmacological management of new onset epilepsy in adults. J Manag Care Pharm. 2006;12(1):55-60.
2. Heaton PC, Guo JJ, Hornung RW, et al. Analysis of the effectiveness and cost benefit of leukotriene modifiers in adults with asthma in the Ohio Medicaid population. J Manag Care Pharm. 2006;12(1):33-42.
3. Robinson RL, Long S, Chang S, et al. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS Antidepressant Medication Management Measures: analysis of administrative claims. J Manag Care Pharm. 2006;12(1):43-54.
4. Winterbottom LM, Fong AM, Benkstein KL, Liang BB, Snodgrass LS, Parks-Huitron H. Impact of a clinical pharmacy consult service on guideline adherence and management of gabapentin for neuropathic pain. J Manag Care Pharm. 2006;12(1):61-69.
5. Hollon SD, Jarrett RB, Nierenberg AA, et al. Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment? J Clin Psychiatry. 2005;66(4):455-68.
6. Nemeroff CB, Heim CM, Thase ME, et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. (published online ahead of print). Proc Natl Acad Sci. 2005;100(24):14293-96.
7. Treatment for Adolescents with Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression. JAMA. 2004;292:807-20.
8. Khan A, Kolts RL, Rapaport MH, Krishnan KR, Brodhead AE, Brown WA. Psychol Med. 2005;35(5):743-39.
9. Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004;363:1341-45.
10. Emslie GJ, Rush AJ, Weiberg WA, et al, A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997;54:1031-37.
11. Emslie GJ, Heiligenstein JH, Wagner JD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002;41:1205-15.
12. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled tirals. J Clin Psychiatry. 2005;66(8):974-81.
13. Hjalmarsson L, Corcos M, Jeammet P. Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks). Encephale. 2005;31(3):309-16.
14. Kahn A, Brodhead AE, Kolts RL, Brown WA. Severity of depressive symptoms and response to antidepressant and placebo in trials of antidepressants. J Psychiatr Res. 2005;39(2):145-50.
15. Khan A, Brodhead AE, Schwartz KA, Kolts RL, Brown WA. Sex differences in antidepressant response in recent antidepressant clinical trials. J Clin Psychopharmacol. 2005;25(4):318-24.
16. Corey-Lisle PK, Nasch R, Stang P, Swindle R. Response, partial response, and nonresponse in primary care treatment of depression. Arch Intern Med. 2004;164:1197-1204.
17. Eaddy MT, Druss BG, Sarnes MW, Regan TS, Frankum LE. Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy: results from a managed care administrative database. J Manag Care Pharm. 2004;11(2):145-50.
18. Simon GE, Ludman EJ, Tutty S, et al. Telephone psychotherapy and telephone care management for primary care patients starting antidepressant treatment - a randomized controlled trial. JAMA. 2004;292:935-42.
19. Ruthven L. Where is the proof that polypharmacy is effective? Drug Benefit Trends. December 2005;554, 557.
20. Barbuto JP. Categorizing patients from medical claims data - the influence of GIGO. J Manag Care Pharm. 2004;10(6):559-60.
21. Curtiss FR. Evidence-based medicine: beware of results from randomized controlled trials and research with administrative claims data. J Manag Care Pharm. 2005;11(2):172.
22. Theobald DE, Kasper M, Nick-Kresl CA, et al. Documentation of indicators for antidepressant treatment and response in an HMO primary care population. J Manag Care Pharm. 2000;6(6):494-98.
23. Crownover BK. Referral bias and other perspectives on the HEDIS measuring stick for quality of care in depression treatment. J Manag Care Pharm. 2006;12(1):76-77.
24. Petrovic M, De Paepe P, van Bortel L. Pharmacotherapy of depression in old age. Acta Clin Belg. 2005;60(3):150-56.
25. FDA Public Health Advisory - Suicidality in children and adolescents being treated with antidepressant medications. October 15, 2004. Available at: http://www.fda.gov/cder/drug/antidepressants/SSRIPHA200410.htm. Accessed December 26, 2005.
26. van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ. 2001;323:655-58.
27. Curtiss FR. Evidence-based medicine: are SSRIs more effective than placebo and what length of therapy is enough? J Manag Care Pharm. 2005;11(2):172-76.
28. Mann JJ, Drug therapy. The medical management of depression. N Engl J Med. 2005;353:1819-34.
29. Amsterdam JD, Maislin G, Potter L. Fluoxetine efficacy in treatment resistant depression. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18:243-61.
30. Rush AJ, Kupfer DJ. Strategies and tactics in the treatment of depression. In: Gabbard GO, ed. Treatment of Psychiatric Disorders. 3rd ed. Washington, D.C.: American Psychiatric Press; 2001:1417-39.
31. McCormick D, Himmelstein DU, Woolhandler S, Wolfe SM, Bor DH. Relationship between low quality-of-care scores and HMOs' subsequent public disclosure of quality-of-care scores. JAMA. 2002;288:1484-90.
32. Kobak KA, Taylor L, Katzelnick DJ, Olson N, Clagnaz P, Henk HJ. Antidepressant medication management and Health Plan Employer Data and Information Set (HEDIS) criteria: reasons for nonadherence. J Clin Psychiatry. 2002;63(8):727-32.
33. Kertesz L. Group aims to raise comparison standards. Mod Healthcare. July 8, 1996:46,48.
34. Glauber JH. Does the HEDIS asthma measure go far enough? Am J Manag Care. 2001;7(6):575-79.
35. National Committee for Quality Assurance (NCQA). HEDIS 2006. Vol. 2. Technical Update. October 1, 2005. Available at: http://www.ncqa.org/Programs/ HEDIS/2006/Volume2/TechnicalUpdate.pdf. Accessed December 26, 2005.
36. Mosen D, Macy E, Schatz M, et al. How well do the HEDIS asthma inclusion criteria identify persistent asthma? Am J Manag Care. 2005;11(10):650-54.
37. Bodenheimer T. The American health care system - the movement for improved quality in health care. N Engl J Med. 1999;340(6):488-92.
38. Oetgen WJ, Wiley MJ. Medical practice guidelines: is cookbook medicine here? Available at: http://72.14.203.104/search?q=cache:QtPrxBcseNgJ: www.afip.org/Departments/legalmed/openfile96/guidelines.pdf+cookbook+ medicine&hl=en. Accessed December 18, 2005.
39. Data from Verispan. Top 200 brand-name drugs by retail dollars in 2004. Drug Top. February 21, 2005:18.
40. Merck & Co., Inc. Other financial disclosures, third quarter 2005. Available at: http://library.corporate-ir.net/library/73/731/73184/items/170444/ 3Q05_other.pdf. Accessed December 26, 2005.
41. Data search performed December 20, 2005, of the data warehouse of a national pharmacy benefits manager representing approximately 500,000 beneficiaries of small employer drug benefit plans for pharmacy claims with dates of service from October 2005 through December 15, 2005.
42. Lakomski PG, Chitre M. Evaluation of the utilization patterns of leukotriene modifiers in a large managed care health plan. J Manag Care Pharm. 2004;10(2):115-21.
43. National Asthma Education and Prevention Program (NAEPP) Expert Panel Report: Guidelines for the diagnosis and management of asthma - update on selected topics 2002. Available at: http://www.nhlbi.nih.gov/ guidelines/asthma/index.htm. Accessed December 18, 2005.
44. Boushey HA, Sorkness CA, King TS, et al. for the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. N Engl J Med. 2005;352:1519-28.
45. Fabbri LM. Does mild persistent asthma require regular treatment? N Engl J Med. 2005;352:1589-91.
46. Auerbach I, Springer C, Godfrey S. Total population survey of the frequency and severity of asthma in 17 year old boys in an urban area of Israel. Thorax. 1993;48:139-41.
47. FDA Center for Drug Evaluation and Research. Application # 20-830, Medical Reviews. Medical Officer Review, January 20, 1998. Available at: http://www.fda.gov/cder/foi/nda/98/20830_Singulair_medr.pdf. Accessed December 18, 2005.
48. Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ. 2003;326:621-25.
49. Montelukast (Singulair) for perennial allergic rhinitis. Med Lett. 2005;47 (1220):87-88.
50. Perry TT, Corren J, Phillip G, et al. Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposure. Ann Allergy Asthma Immunol. 2004;93(5):431-38.
51. Nathan RA, Yancey SW, Waitkus-Edwards K, et al. Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest. 2005;128(4):1910-20.